EMPAVELI® is administered subcutaneously at a dose of 1,080 mg twice weekly for the treatment of PNH.

Dosage and Administration of EMPAVELI

The recommended dosage of EMPAVELI® for the treatment of PNH in adults is 1,080 mg administered subcutaneously twice weekly. The drug can be delivered using a commercially available pump or with the EMPAVELI Injector. It is essential to follow the provided instructions on preparation and administration to ensure proper dosing. Any changes in the patient’s condition or response to therapy should be reviewed by the healthcare provider to evaluate whether dosing adjustments are necessary. Careful administration techniques are required to avoid injection site reactions or errors.